Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial

Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment